ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 81 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q2 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $22,000 | -86.2% | 10,800 | -74.5% | 0.00% | – |
| Q4 2021 | $159,000 | -3.6% | 42,389 | +33.0% | 0.00% | – |
| Q3 2021 | $165,000 | +175.0% | 31,881 | +127.8% | 0.00% | – |
| Q2 2021 | $60,000 | -70.4% | 13,997 | -63.4% | 0.00% | -100.0% |
| Q1 2021 | $203,000 | -32.3% | 38,213 | -31.4% | 0.00% | -50.0% |
| Q4 2020 | $300,000 | -40.6% | 55,700 | -12.0% | 0.00% | -71.4% |
| Q3 2020 | $505,000 | +1385.3% | 63,285 | +404.2% | 0.01% | +600.0% |
| Q1 2020 | $34,000 | -94.5% | 12,552 | -88.4% | 0.00% | -85.7% |
| Q4 2018 | $622,000 | +4.4% | 108,100 | +115.3% | 0.01% | -12.5% |
| Q2 2018 | $596,000 | +27.9% | 50,200 | +21.0% | 0.01% | +14.3% |
| Q1 2018 | $466,000 | +166.3% | 41,500 | +58.4% | 0.01% | +133.3% |
| Q4 2017 | $175,000 | +21.5% | 26,200 | +49.3% | 0.00% | 0.0% |
| Q3 2017 | $144,000 | – | 17,554 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 12,025,999 | $66,263,000 | 2.30% |
| Abingworth LLP | 250,000 | $1,375,000 | 1.02% |
| Tekla Capital Management LLC | 1,466,368 | $8,080,000 | 0.31% |
| Rock Springs Capital Management LP | 875,000 | $4,821,000 | 0.28% |
| QVT Financial LP | 1,360,647 | $6,940,000 | 0.22% |
| Vident Investment Advisory, LLC | 232,641 | $1,282,000 | 0.13% |
| Hillhouse Capital Management | 1,190,476 | $6,560,000 | 0.13% |
| Orbimed Advisors | 1,914,660 | $10,550,000 | 0.12% |
| Granite Investment Partners, LLC | 195,571 | $1,078,000 | 0.07% |
| Monashee Investment Management LLC | 25,000 | $138,000 | 0.06% |